Expression Pattern of a New Marker, Gl7 in Different Stages of B-Cell Maturation and Its Utility in B-Lymphoblastic Leukemia/Lymphoma Measurable Residual Disease Assessment.

Correspondence to: docprt@gmail.com I Background: i Increasing use of targeted therapies such as anti-CD19 Blinatumomab/CAR-T-cells and anti-CD20 rituximab obviates the need for additional B-cell maturation-associated markers to evaluate deviation from normal in bone marrow (BM) in patients with B-lymphoblastic leukemia/lymphoma (B-ALL) by multicolor flow cytometry (MFC). I Conclusion: i GL7 appears in B-cell maturation in BM at late BCP2 stage and is expressed in a proportion of B-ALL patients. [Extracted from the article]